Estrogen replacement therapy and gallbladder disease in postmenopausal women

Menopause

Volumn 7, Issue 3, 2000, Pages 162-167

  Uhler, Meike L ^a   Marks, Jay W ^b   Judd, Howard L ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholesterol crystals; Cholesterol saturation index; Gallstone formation

Indexed keywords

BILE ACID; CHOLESTEROL; ESTROGEN;

ARTICLE; DISEASE MARKER; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; GALLBLADDER DISEASE; GALLSTONE FORMATION; HUMAN; INCIDENCE; POSTMENOPAUSE;

EID: 0034114170     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200007030-00006     Document Type: Article

References (47)

1. Steingold KA, Laufer L, Chetkowski RJ, Matt DW, Meldrum DR, Judd HL. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
2. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160:176-81.
3. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of post-menopausal bone loss. Obstet Gynecol 1984;63:759-64.
4. Stampfer MJ, Colditz GA, Willett WC, et al. Post-menopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991;325:756-62.
5. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974;290(1):15-9.
6. Small DM. The etiology and pathogenesis of gallstones. Adv Surg 1976;10:63-85.
7. Carey MC. Formation of gallstones: the new paradigms. In: Paumgartner G, Stiehl A, eds. Trends in bile acid research. London: Dordrecht Academic Publishers, 1988:259-81.
8. Carey MC, Ko G. The importance of total lipid concentration in determining cholesterol solubility in bile and the development of critical tables for calculating percent cholesterol saturation with a correction factor for ursodeoxycholate-rich bile. In: Paumgartner G, Stiehl A, Gerok W, eds. Biological effects of bile acids. Baltimore: University Park Press, 1979:299-308.
9. Marks JW, Broomfield P, Bonorris GG, Schoenfield LJ. Factors affecting the measurement of cholesterol nucleation in human gallbladder and duodenal bile. Gastroenterology 1991;101:214-9.
10. Holan KR, Holzbach RT, Hermann RE, Cooperman Am, Claffey WJ. Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979;77:611-7.
11. Lee SP, La Mont JT, Carey MC. The role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones: studies in the prairie dog. J Clin Invest 1981;67:1712-33.
12. Gallinger S, Taylor RD, Harvey PR, Petrunka CN, Strasberg SM. Effect of mucous glycoprotein on nucleation time in human bile. Gastroenterology 1985;98:648-58.
13. Smith BF, La Mont JT. Identification of gallbladder mucin-bilirubin complex in human cholesterol gallstone matrix: effects of reducing agents on in vitro dissolution of matrix and intact gallstones. J Clin Invest 1985;76:429-35.
14. Sedaghat A, Grundy SM, Cholesterol crystals and the formation of cholesterol gallstones. N Engl J Med 1980;302:1274-7.
15. LaMorte WW, La Mont JT, Hale W, Booker ML, Scott TE, Turner B. Gallbladder prostaglandins and lysophospholipids as mediators of mucin secretion during cholelithiasis. Am J Physiol 1986;251:G701-9.
16. Hoaner EL, Jaffe BM, Webb H, England DW. Effects of female sex hormones and pregnancy on gallbladder prostaglandin synthesis. Arch Surg 1988;123:705-8.
17. Broomfield PH, Chopra R, Sheinbaum RC, et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med 1988;319:1567-72.
18. Marks JW, Bonorris GG, Albers G, Schoenfield LJ. The sequence of events during the formation of cholesterol gallstones in man. Hepatology 1990;12:325A.
19. Marks JW, Bonorris GG, Schoenfield LJ. Roles of deoxycholate and arachidonate in pathogenesis of cholesterol gallstones in obese patients during rapid loss of weight. Dig Dis Sci 1991;36:957-60.
20. Marks JW, Bonorris GG, Schoenfield LJ. Effects of ursodiol or ibuprofen on contractions of gallbladder and bile among obese patients during weight loss. Dig Dis Sci 1996;41:242-9.
21. Marks JW, Bonorris GG, Albers G, Schoenfield LJ. The sequence of biliary events preceding the formation of gallstones in humans. Gastroenterology 1992;103:556-70.
22. Lee DWT, Gilmore CJ, Bonorris G, et al. Effect of dietary cholesterol on biliary lipids in patients with gallstones and normal subjects. Am J Clin Nutr 1985;42:414-20.
23. Schreiber AJ, Simon FR. Estrogen induced cholestasis: clues to pathogenesis and treatment. Hepatology 1983;3:607-13.
24. Lynn J, Wiliams L, O'Brien J, Wittenberg J, Egdahl RH. Effects of estrogen upon bile: implications with respect to gallstone formation. Ann Surg 1973;178:514-24.
25. Heuman R, Larsson-Cohn U, Hammar M, Tiselius H-G. Effects of postmenopausal ethinylestradiol treatment on gallbladder bile. Maturitas 1979;2:69-72.
26. Vore M. Estrogen cholestasis: membranes, metabolites and receptors. Gastroenterology 1987;93:643-9.
27. D'Amato G, Cavallini A, Messa C, Mangini V, Misciagna G. Serum and bile lipid levels in postmenopausal women after percutaneous and oral natural estrogens. Am J Obstet Gynecol 1989;160(3):600-1.
28. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease and breast tumors. Lancet 1973;1:1399-404.
29. Grodstein F, Colditz GA, Hunter DJ, Manson JE, Willett WC, Stampfer MJ. A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors. Obstet Gynecol 1994;84(2):207-14.
30. Henriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen-induced gallstone formation in males. J Clin Invest 1989;84:811-6.
31. The Coronary Drug Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism. N Engl J Med 1977;296:1185-90.
32. Petitti DB, Sidney S, Perlman JA. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology 1988;94:91-5.
33. Grodstein F, Colditz GA, Stamper MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83(1):5-11.
34. Nachtigall LE, Nachtigall LH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74-9.
35. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
36. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
37. Laufer LR, De Fazio JL, Lu JK, et al. Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 1983;146(5):533-40.
38. Judd HL. Effects of estrogen replacement on hepatic function. In: Mishell DR, ed. Menopause: physiology and pharmacology. Chicago: Year Book Medical Publishers, 1987:237-51.
39. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
40. Everson GT, McKinley C, Kern F. Mechanisms of gallstone formation in women. J Clin Invest 1991;87:237-46.
41. Van Erpecum KJ, van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FLH. Different hepatobiliary effects of transdermal and oral estradiol in postmenopausal women. Gastroenterology 1991;100(2):482-8.
42. Marks JW, Uhler ML, Bonorris GG, Judd HL. Nucleation of biliary cholesterol, arachidonate, prostaglandin E2 and glycoproteins in postmenopausal women. Gastroenterology 1997;112:1271-6.
43. Uhler ML, Marks JW, Voigt BJ, Judd HL. Comparison of the impact of transdermal versus oral estrogen on biliary markers of gallstone formation in postmenopausal women. J Clin Endocrinol Metab 1998;83:410-4.
44. Honore LH. Increased incidence of symptomatic cholesterol cholelithiases in peri-menopausal women receiving estrogen replacement therapy: a retrospective study. J Reprod Med 1980;187-90.
45. Jorgensen T. Gallstones in a Danish population: fertility period, pregnancies, and exogenous female sex hormones. Gut 1988;29:433-9.
46. Kakar F, Weiss NS, Strite SA. Noncontraceptive estrogen use and the risk of gallstone disease in women. Am J Public Health 1988;78:564-6.
47. Petitti DB, Friedman GD, Klatsky AL. Association of a history of gallbladder disease with a reduced concentration of high density-lipoprotein cholesterol. N Engl J Med 1981;304:1396-8.